Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukemia

Published: 7 October 2019| Version 2 | DOI: 10.17632/br223h8sdd.2
Jeremy Schraw


Normalized, scaled metabolite abundance data from an experiment involving profiling of diagnostic bone marrow plasma samples from N=155 children with acute lymphoblastic leukemia. Patients were diagnosed at Texas Children's Hospital between 2007-15 and treated on or according to Children's Oncology Group frontline ALL protocols. Metabolomics data were generated from 2017-18 using the Metabolon Global Metabolomics platform. Missing values have been imputed with the minimum. Data are annotated with sex; race/ethnicity; height, weight, age, and white blood cell count at diagnosis; NCI risk group; cytogenetic category; central carbon metabolism cluster membership derived from metabolite set enrichment analysis and hierarchical clustering analyses; end-induction minimal residual disease (MRD) status; and relapse status if known. Data are divided into a discovery (N=93) and replication (N=62) partition.



Baylor College of Medicine


Cancer, Biomarker in Leukemia, Acute Leukemia